Bolt Biotherapeutics, Inc. Common Stock (BOLT) is a publicly traded Healthcare sector company. As of May 21, 2026, BOLT trades at $4.63 with a market cap of $8.38M and a P/E ratio of -0.28. BOLT moved -6.25% today. Year to date, BOLT is -18.55%; over the trailing twelve months it is -30.09%. Its 52-week range spans $3.91 to $14.36. Analyst consensus is buy with an average price target of $30.33. Rallies surfaces BOLT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Bolt Biotherapeutics Reports $4.31 Q1 Loss, Misses Revenue Estimates: Bolt Biotherapeutics posted a loss of $4.31 per share in Q1, missing the consensus loss estimate of $2.85 and improving from a $5.80 per-share loss a year ago. Revenues also fell short of analysts' projections, reflecting a sequential decline in top-line performance.
| Metric | Value |
|---|---|
| Price | $4.63 |
| Market Cap | $8.38M |
| P/E Ratio | -0.28 |
| EPS | $-16.40 |
| Dividend Yield | 0.00% |
| 52-Week High | $14.36 |
| 52-Week Low | $3.91 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $6.50M |
| Net Income | $-29.58M |
| Gross Margin | 0.00% |
3 analysts cover BOLT: 0 strong buy, 2 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $30.33.